Aptus Capital Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$64.3K Buy
587
+3
+0.5% +$334 ﹤0.01% 1342
2026
Q2
$63.9K Sell
584
-15
-3% -$1.55K ﹤0.01% 1350
2026
Q1
$62.2K Buy
599
+38
+7% +$4.05K ﹤0.01% 1246
2025
Q4
$57.9K Buy
561
+33
+6% +$3.21K ﹤0.01% 1273
2025
Q3
$47.7K Buy
528
+4
+0.8% +$350 ﹤0.01% 1238
2025
Q2
$46.1K Buy
524
+3
+0.6% +$260 ﹤0.01% 1193
2025
Q1
$47.5K Sell
521
-10
-2% -$901 ﹤0.01% 1111
2024
Q4
$45.8K Sell
531
-500
-48% -$45.2K ﹤0.01% 1118
2024
Q3
$98K Hold
1,031
– – ﹤0.01% 854
2024
Q2
$94.3K Hold
1,031
– – ﹤0.01% 827
2024
Q1
$93.5K Buy
+1,031
New +$90.3K ﹤0.01% 829

Other funds holding PPH

Aptus Capital Advisors's PPH Position: Q3 2026 in Review

Aptus Capital Advisors increased its VanEck Pharmaceutical ETF (PPH) stake by 0.51% in Q3 2026, buying an estimated $334 and bringing the position to 587 shares worth $64.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1342.

Aptus Capital Advisors first reported a position in PPH in Q1 2024 and has held it in 11 quarters since. The position peaked at $98K in Q3 2024. 154 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • Aptus Capital Advisors held 587 shares of VanEck Pharmaceutical ETF worth $64.3K as of Q3 2026.
  • Aptus Capital Advisors bought 3 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $334.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q3 2026, its #1342 holding.
  • Aptus Capital Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and has held it in 11 quarters since.
  • Aptus Capital Advisors's VanEck Pharmaceutical ETF position peaked at $98K in Q3 2024.
  • 154 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on Aptus Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.